NOTE: Many features on this website require Javascript and cookies. You can enable both via your browser's preference settings.
NEJM - 18/07/2007 21:55:19
In a randomized trial, 2161 patients with peripheral arterial disease were assigned to combination therapy with an antiplatelet agent and an oral anticoagulant or to antiplatelet therapy alone. At a mean follow-up of 35 months, the rate of myocardial infarction, stroke, or death from cardiovascular causes was not significantly different between the two groups. The group receiving combination therapy had a significantly higher rate of life-threatening bleeding.
using both antiplatlet and anticoagulant is over treatment no need for that
Sign in or register to comment on this story